Sign in Subscribe
Pharmaceutical industry

Carrington Laboratories Receives European Patent for Aloe Pectins

Strategic Insights

— 1 min read

Carrington Laboratories' subsidiary, DelSite Biotechnologies, has secured a significant intellectual property advantage in the field of controlled-release drug delivery technologies. The European Patent Office has issued European Patent No. EP 1 086 141 B1 for "Aloe Pectins," a patent that broadly covers the use of DelSite's proprietary GelSite polymer technology. This technology has far-reaching applications, including pharmaceutical compositions, vaccine antigens, and other pharmacological substances.

Key Takeaways:

  • DelSite Biotechnologies, a wholly-owned subsidiary of Carrington Laboratories, has developed a proprietary drug delivery technology called GelSite polymer, which has received its first European patent (European Patent No. EP 1 086 141 B1).
  • The newly issued patent describes the composition and process of manufacturing high-molecular-weight and low-molecular-weight pectins from Aloe vera, applicable to any use of DelSite's Aloe pectins.
  • The patent claims are broadly applicable to pharmaceutical compositions, including proteins, peptides, vaccine antigens, and other pharmacological substances.
  • GelSite polymer has unique functional properties, including in situ gellation and the ability to stabilize many proteins, making it an attractive basis for novel drug delivery systems, such as the GelVac nasal powder vaccine delivery system.
  • DelSite's most advanced delivery platform, GelVac, is a simple and broad nasal powder vaccine delivery system suitable for various classes of vaccine antigens.
  • In May 2005, DelSite announced results of a phase I clinical trial demonstrating that the GelSite polymer and GelVac system were safe and well-tolerated, with consistent and reproducible delivery to the nasal cavity.
  • A Drug Master File (DMF) for the use of GelSite polymer in mucosal applications has been filed with the FDA, and preclinical development is underway for an Avian influenza vaccine.

Statistics:

  • European Patent No.: EP 1 086 141 B1
  • Date of clinical trial announcement: May 2005
  • Number of healthy volunteers in the phase I clinical trial: 15
  • Year in which preclinical development began for the Avian influenza vaccine: Not specified

Sources:

  • Carrington Laboratories, Inc. press release announcing the European patent
  • Health & Medicine Week, 2005 (via NewsRx.com) article: "Carrington Laboratories, Inc.: Carrington Laboratories, Inc. Subsidiary DelSite Biotechnologies, Inc. Receives European Patent for Patent Application for "Aloe Pectins" Featuring Polysaccharide Comprising GelSite Polymer, Proprietary Technology That Is Ideal for Delivery of Vaccine or Immunogenic Substance in Mucosal Application"

Read more